Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Tadalafil for Duchenne Muscular Dystrophy

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Tadalafil for Duchenne Muscular Dystrophy

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 22 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tadalafil (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Registrational; Therapeutic Use
  • Sponsors Eli Lilly and Company
  • Most Recent Events

    • 11 Mar 2022 According to a PTC Therapeutics media release, results evaluating associations between Deflazacort vs Prednisone/prednisolone and disease progression markers in subgroup of patients with Duchenne Muscular Dystrophy (NCT01826487, NCT01865084, NCT00592553, NCT01254019) will be presented at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference 2022. Abstract is available on the MDA Conference website.
    • 25 Feb 2016 Planned End Date changed from 1 Apr 2018 to 1 Mar 2016 as reported by ClinicalTrials.gov record.
    • 10 Feb 2016 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top